Kala Pharmaceuticals logo
Kala Pharmaceuticals KALA
$ 2.73 -9.6%
report update icon

Quarterly report 2026-Q2
added 08-19-2026

Kala Pharmaceuticals Revenue | KALA

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Kala Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 3.89 M 11.2 M 6.36 M 6.07 M - - - 45 K - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
11.2 M 45 K 5.52 M

Quarterly Revenue Kala Pharmaceuticals

2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - - - - - - - - - 420 K 2.1 M 1.37 M - 3.07 M 3.05 M 3.27 M 2.24 M 2.22 M 833 K 1.07 M 1.18 M 1.45 M 2.06 M 1.39 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
3.27 M 420 K 1.84 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
PainReform Ltd. PainReform Ltd.
PRFX
17 K $ 0.47 -24.53 % $ 305 K israelIsrael
iTeos Therapeutics iTeos Therapeutics
ITOS
35 M - - $ 411 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
405 K $ 1.44 -2.03 % $ 2.37 M israelIsrael
PolarityTE PolarityTE
PTE
814 K - -0.82 % $ 1.78 M usaUSA
Kronos Bio Kronos Bio
KRON
9.85 M - 1.49 % $ 50.8 M usaUSA
Cullinan Management Cullinan Management
CGEM
18.9 M $ 8.9 -1.93 % $ 536 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
3.51 M $ 39.15 0.57 % $ 3.52 B schweizSchweiz
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
184 M $ 26.77 -0.59 % $ 1.59 B usaUSA
Trevena Trevena
TRVN
567 K - -46.58 % $ 31.8 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
9.75 M - -10.95 % $ 876 K usaUSA
Molecular Templates Molecular Templates
MTEM
18.8 M - -23.43 % $ 495 K usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
642 K $ 0.07 9.81 % $ 855 K usaUSA
Novan Novan
NOVN
23.7 M - -24.84 % $ 2.64 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
-416 K - -1.56 % $ 12.3 M usaUSA
Epizyme Epizyme
EPZM
37.4 M - - $ 249 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
54 K - -6.81 % $ 3.04 B usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
36.9 M - - $ 4.55 M irlandaIrlanda
scPharmaceuticals scPharmaceuticals
SCPH
36.3 M - - $ 218 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
7 M - - $ 105 M usaUSA
Athersys Athersys
ATHX
5.32 M - 3.77 % $ 22.4 M usaUSA
Global Blood Therapeutics Global Blood Therapeutics
GBT
195 M - - $ 4.62 B usaUSA
NanoString Technologies NanoString Technologies
NSTG
127 M - -37.43 % $ 5.1 M usaUSA
Humanigen Humanigen
HGEN
2.51 M - -81.12 % $ 4.28 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
62.8 M - -29.58 % $ 126 M usaUSA
Surface Oncology Surface Oncology
SURF
30 M - - $ 59.7 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
300 K - -0.05 % $ 1.34 B canadaCanada
Vaccinex Vaccinex
VCNX
601 K - -61.37 % $ 654 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
5 K - -19.68 % $ 18.4 M canadaCanada
Jounce Therapeutics Jounce Therapeutics
JNCE
82 M - - $ 98.4 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
2.01 M $ 0.93 -4.11 % $ 10.5 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
63.3 M $ 1.89 6.78 % $ 52.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
118 M - -24.86 % $ 820 K usaUSA
Longeveron Longeveron
LGVN
1.2 M $ 1.65 -9.34 % $ 29 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
469 K - -11.43 % $ 502 K usaUSA
Mersana Therapeutics Mersana Therapeutics
MRSN
40.5 M - - $ 3.56 B usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
368 K $ 6.83 1.71 % $ 460 B britainBritain
MediWound Ltd. MediWound Ltd.
MDWD
21.8 M $ 13.59 0.33 % $ 370 M israelIsrael
CymaBay Therapeutics CymaBay Therapeutics
CBAY
31.1 M - - $ 3.45 B usaUSA
Keros Therapeutics Keros Therapeutics
KROS
244 M $ 11.04 -3.07 % $ 411 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
42 K $ 4.9 -8.75 % $ 75.9 M australiaAustralia